MO-2097

MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the RAF/MEK/ERK signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer[1][2].

Product Specifications

CAS Number

[2744300-63-6]

UNSPSC

12352005

Target

Apoptosis; Caspase; ERK; HIF/HIF Prolyl-Hydroxylase; MEK; Raf; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

OC1=CC(C2=CC3=C(C=C4OCC(C)=CCC4=C3)O2)=CC(O)=C1

Molecular Formula

C19H16O4

Molecular Weight

308.33

References & Citations

[1]Kim S, et al. MO-2097 inhibits EMT and angiogenesis in colorectal cancer by targeting RAF/MEK/ERK signaling. Sci Rep. 2025 Jul 1;15 (1) :21781.|[2]Han HJ, et al. HIF-1α inhibition by MO-2097, a novel chiral-free benzofuran targeting hnRNPA2B1. J Adv Res. 2024 Oct;64:67-81.